Did BMS set up a subsidiary to avoid paying $1.4B in US taxes? The Senate finance chairman is on the casenews2022-01-19T14:41:59+00:00January 19th, 2022|Fierce Pharma|
As Pfizer’s Cibinqo grabs an FDA green light, JAK inhibitors’ entry into the eczema market ‘has split doctors’ opinion: reportnews2022-01-19T13:11:00+00:00January 19th, 2022|Fierce Pharma|
Apprentice.io scores $100M funding for augmented reality tech that helped drug plants work through COVID-timenews2022-01-19T05:04:29+00:00January 19th, 2022|Fierce Pharma|
Fierce JPM Week: Despite pandemic’s challenges, collaboration in biopharma is ‘alive and well,’ panel saysnews2022-01-18T19:40:53+00:00January 18th, 2022|Fierce Pharma|
AstraZeneca climbs a Himalaya to find ill-fated treme a place alongside Imfinzi in liver cancernews2022-01-18T18:18:18+00:00January 18th, 2022|Fierce Pharma|
Merck’s Keytruda narrowly passes liver cancer confirmatory trial, but murky FDA fate lies aheadnews2022-01-18T16:40:58+00:00January 18th, 2022|Fierce Pharma|
FDA extends decision dates on bluebird bio’s gene therapy drugs beti-cel and eli-cel by 3 monthsnews2022-01-18T16:15:08+00:00January 18th, 2022|Fierce Pharma|
The wait is over: AbbVie’s Rinvoq chalks up FDA win with favorable atopic dermatitis labelnews2022-01-18T15:44:43+00:00January 18th, 2022|Fierce Pharma|
Inside the Catalent FDA citation said to trigger Novo Nordisk’s Wegovy supply hiccupnews2022-01-18T14:39:05+00:00January 18th, 2022|Fierce Pharma|
Hikma shells out $45.75M to buy bankrupt Teligent’s Canadian assetsnews2022-01-18T14:27:31+00:00January 18th, 2022|Fierce Pharma|
